Wilson Disease in South America

Cançado, Eduardo Luiz Rachid; Barbosa, Egberto Reis

doi:10.1016/b978-0-12-810532-0.00031-8

Cited by 1 publication

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current series provides a comprehensive overview of our experience with WD, from diagnosis to treatment and outcomes over the past 7 decades. Previous publications have focused on specific aspects of subgroups of this cohort, [20][21][22][23][24] such as genotype-phenotype correlation, neurologic manifestations, and rare presentations. However, long-term follow-up data could provide food for thought for better management of WD.…”

Section: Discussionmentioning

confidence: 99%

Wilson disease: the diagnostic challenge and treatment outcomes in a series of 262 cases

Deguti,

Araujo,

Terrabuio

et al. 2024

Arq Neuropsiquiatr

View full text Add to dashboard Cite

Background Wilson disease (WD) is an autosomal recessive disorder that leads to organ toxicity due to copper overload. Early diagnosis is complicated by the rarity and diversity of manifestations. Objective To describe the diagnostic features and response to treatment in our cohort of WD patients. Methods This was a retrospective analysis of 262 WD patients stratified by clinical presentation, complementary exams, ATP7B genotyping, and response to treatment. Results Symptoms occurred at an average age of 17.4 (7–49) years, and patients were followed up for an average of 9.6 (0–45) years. Patients presented mainly with hepatic (36.3%), neurologic (34.7%), and neuropsychiatric (8.3%) forms. Other presentations were hematologic, renal, or musculoskeletal, and 16.8% of the patients were asymptomatic. Kayser-Fleischer rings occurred in 78.3% of the patients, hypoceruloplasminemia in 98.3%, and elevated cupruria/24h in 73.0%, with an increase after D-penicillamine in 54.0%. Mutations of the ATP7B gene were detected in 84.4% of alleles. Brain magnetic resonance imaging showed abnormalities in the basal ganglia in 77.7% of patients. D-penicillamine was the first choice in 93.6% of the 245 patients, and 21.1% of these patients were switched due to adverse effects. The second-line therapies were zinc and trientine. The therapeutic response did not differ significantly between the drugs (p = 0.2). Nine patients underwent liver transplantation and 82 died. Conclusion Wilson disease is diagnosed at a late stage, and therapeutic options are limited. In people under 40 years of age with compatible manifestations, WD could be considered earlier in the differential diagnosis. There is a need to include ATP7B genotyping and therapeutic alternatives in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%